Slide 1: ADHERE Study Topline Results
ADHERE Study T opline Results July 17 , 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Positive Topline Results
Stage A Response Rate Primary Endpoint Safety and Tolerability Study met primary endpoint (p=0.000039); VYVGART ® Hytrulo demonstrated a 61% reduction ( HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse compared to placebo based on time to first adjusted INCAT deterioration 67% of patients demonst
Slide 4: Our mission is to transform severe autoimmunity
4 Our mission is to transform severe autoimmunity Raising expectations for what ‘well - controlled’ means for patients Redefining autoimmune diseases as IgG - mediated
Slide 5: A Historic Day for CIDP Patients
Bringing Hope to Patients of New Treatment Option A Historic Day for CIDP Patients I was the type of woman that would run first thing in the morning before work, and then CIDP hit, and it was like hitting the wall at a hundred miles an hour. Crystal Living With CIDP Largest Global CIDP Trial New sta
Slide 6: CIDP Patients in Desperate Need of New Options
CIDP Patients in Desperate Need of New Options argenx market research, Burt et al. 2021, GBS |CIDP Foundation International 30% of patients progress to a wheelchair if left untreated Feelings of i solation , depression and being misunderstood Required to balance tradeoffs between side effects and sy
Slide 7: Innovative ADHERE Design
Innovative ADHERE Design Patients need to demonstrate disease worsening off - treatment based on INCAT, I - RODS, grip strength Clinical Confirmation Committee Treatment Period Confirm IgG involvement Assess e fficacy and safety Run - in period Stage A Stage B Screening ≤ 12 weeks ≤ 4 weeks VYVGART
Slide 8: Baseline Characteristics
Baseline Characteristics STAGE A STAGE B VYVGART Hytrulo (N=322) VYVGART Hytrulo (N=111) Placebo (N=110) Age - Mean years (SD) 54.0 (13.9) 54.5 (13. 2 ) 51.3 (14. 5 ) Females - n (%) 114 (35.4) 38 (34.2) 41 (37.3) Time Since Diagnosis - Mean years (SD) 4.9 (6. 1 ) 3.7 (4.4) 3.8 (4. 7 ) Atypical CIDP
Slide 9: Stage A Response Rate
* Excluding patients ongoing in Stage A at the time of the 88th event who did not have the full opportunity to achieve a resp ons e Patients needed to demonstrate evidence of clinical improvement (ECI) to be a responder and advance to Stage B A responder demonstrated ECI on the INCAT score, or impro
Slide 10: Stage B: Relative Risk of Relapse Based on Time to First Adjusted INCAT Deterioration
Clinical benefit observed across all efficacy scales and patient subgroups, regardless of prior therapy P rimary endpoint met HR: 0.39 p = 0.000039 S t age B: Relative Risk of Relapse Based on Time to First Adjusted INCAT Deterioration demonstrat ing a 61% lower risk of relapse based on time to firs
Slide 11: Secondary Endpoints
Secondary Endpoints Measure VYVGART Hytrulo n (%) Placebo n (%) Hazard Ratio HR (95% CI) P - value Risk of CIDP Disease Progression Time to First I - RODS Deterioration of at least 4 points - - 0.5 4 (0.35; 0.81) 0.0034 Improved Functional Level I - RODS Improvement of at least 4 points from Stage B
Slide 12: Favorable and Consistent Safety Profile
Favorable and Consistent Safety Profile 12 STAGE A STAGE B VYVGART Hytrulo (N= 322 ) n (%) VYVGART Hytrulo (N= 111 ) n (%) Placebo (N= 110 ) n (%) Number of patients with an Adverse Event (AE) 204 (63.4) 71 (64) 62 (56.4) Number of patients with AEs deemed related by investigator 101 (34.4) 27 (24.3
Slide 13: Opportunity to Revolutionize the CIDP Patient Experience
Opportunity to Revolutionize the CIDP Patient Experience Tomorrow’s Innovation Broad and sustained response Established safety and tolerability 30 - 90 sec ond injection Yesterday’s Standard Of Care 16K PATIENTS Steroids IVIg SCIg PLEX 2g/kg per 2 - 5 days every few weeks 60 mg/day oral 1000mg/ wk I
Slide 14: Building Leadership Within Neuromuscular
Building Leadership Within Neuromuscular 14
Slide 15: argenx Continues To Deliver On Its Promise
argenx Continues To Deliver On Its Promise 75 131 173 218 21 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 US* Regulatory Clinical R evenues EU JP UK IL CN * * VYVGART Hytrulo is approved 4/4 PoC 4/4 Registrational VYVGART Product net sales in #039;M 15
Slide 16: Our mission continues…
16 Our mission continues… Humility Innovation Excellence Co - Creation Empowerment